[#item_full_content]
CANTON, Mass.–(BUSINESS WIRE)– #BKVAN–Orthogon Therapeutics, a developer of novel antiviral medicines, today announced the closing of an oversubscribed financing round, exceeding its $5M target and bringing total funding to over $25M. This funding will accelerate the development of its first-in-class treatments for managing BK virus reactivation in transplant patients. The company has successfully developed small molecule drugs that directly target viral proteins essential to the polyomavirus life cy